Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sirnaomics Ltd. ( (HK:2257) ) just unveiled an update.
Sirnaomics reported its audited 2025 annual results, highlighting resilience amid a difficult global economy and continued advancement of its RNAi therapeutic pipeline. The company emphasized strategic restructuring and operational efficiency as key drivers that have positioned it for sustainable growth.
The lead candidate STP705 progressed toward a Phase III trial in non-melanoma skin cancer and completed a Phase I study in focal fat reduction with strong safety and efficacy, with preparations under way for Phase II and an adaptive Phase II/III design in consultation with the U.S. FDA. STP707 completed a Phase I trial in 50 patients with advanced solid tumors, showing robust safety and therapeutic benefits, particularly in pancreatic cancer, and Sirnaomics is now pursuing potential partnerships for Phase II combination studies.
The full clinical study report for STP707 was submitted to the FDA, confirming IV safety, absence of dose-limiting toxicities and stable disease activity in several tumor types, reinforcing the program’s potential value in oncology. In parallel, the firm advanced its GalAhead platform by completing the second cohort of a Phase I trial for STP122G in coagulation disorders, demonstrating strong safety and dose-dependent target silencing, which supports its broader ambitions in RNAi-based therapeutics.
The most recent analyst rating on (HK:2257) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Sirnaomics Ltd. stock, see the HK:2257 Stock Forecast page.
More about Sirnaomics Ltd.
Sirnaomics Ltd. is a biopharmaceutical company focused on developing RNA interference (RNAi) therapeutics. Its primary programs target non-melanoma skin cancers, focal fat reduction and solid tumors, alongside a GalAhead platform aimed at coagulation disorders, positioning the firm within the oncology, aesthetics and hematology markets.
Average Trading Volume: 295,484
Technical Sentiment Signal: Sell
Current Market Cap: HK$616.6M
Learn more about 2257 stock on TipRanks’ Stock Analysis page.